410 related articles for article (PubMed ID: 27429982)
1. CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection.
Chen P; Zhao W; Guo Y; Xu J; Yin M
Biomed Res Int; 2016; 2016():8090918. PubMed ID: 27429982
[TBL] [Abstract][Full Text] [Related]
2. CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
Subbarayan MS; Joly-Amado A; Bickford PC; Nash KR
Pharmacol Ther; 2022 Mar; 231():107989. PubMed ID: 34492237
[TBL] [Abstract][Full Text] [Related]
3. Microglial Cx3cr1 knockout reduces prion disease incubation time in mice.
Grizenkova J; Akhtar S; Brandner S; Collinge J; Lloyd SE
BMC Neurosci; 2014 Mar; 15():44. PubMed ID: 24655482
[TBL] [Abstract][Full Text] [Related]
4. Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa.
Zabel MK; Zhao L; Zhang Y; Gonzalez SR; Ma W; Wang X; Fariss RN; Wong WT
Glia; 2016 Sep; 64(9):1479-91. PubMed ID: 27314452
[TBL] [Abstract][Full Text] [Related]
5. Fractalkine/CX3CR1 is involved in the cross-talk between neuron and glia in neurological diseases.
Luo P; Chu SF; Zhang Z; Xia CY; Chen NH
Brain Res Bull; 2019 Mar; 146():12-21. PubMed ID: 30496784
[TBL] [Abstract][Full Text] [Related]
6. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.
Pawelec P; Ziemka-Nalecz M; Sypecka J; Zalewska T
Cells; 2020 Oct; 9(10):. PubMed ID: 33065974
[TBL] [Abstract][Full Text] [Related]
7. Fractalkine in the nervous system: neuroprotective or neurotoxic molecule?
Lauro C; Catalano M; Trettel F; Limatola C
Ann N Y Acad Sci; 2015 Sep; 1351():141-8. PubMed ID: 26084002
[TBL] [Abstract][Full Text] [Related]
8. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
Lee S; Varvel NH; Konerth ME; Xu G; Cardona AE; Ransohoff RM; Lamb BT
Am J Pathol; 2010 Nov; 177(5):2549-62. PubMed ID: 20864679
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin S contributes to microglia-mediated olfactory dysfunction through the regulation of Cx3cl1-Cx3cr1 axis in a Niemann-Pick disease type C1 model.
Seo Y; Kim HS; Kang I; Choi SW; Shin TH; Shin JH; Lee BC; Lee JY; Kim JJ; Kook MG; Kang KS
Glia; 2016 Dec; 64(12):2291-2305. PubMed ID: 27687148
[TBL] [Abstract][Full Text] [Related]
10. Absence of CX3CR1 impairs the internalization of Tau by microglia.
Bolós M; Llorens-Martín M; Perea JR; Jurado-Arjona J; Rábano A; Hernández F; Avila J
Mol Neurodegener; 2017 Aug; 12(1):59. PubMed ID: 28810892
[TBL] [Abstract][Full Text] [Related]
11. Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.
Mecca C; Giambanco I; Donato R; Arcuri C
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361745
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents.
Poniatowski ŁA; Wojdasiewicz P; Krawczyk M; Szukiewicz D; Gasik R; Kubaszewski Ł; Kurkowska-Jastrzębska I
Mol Neurobiol; 2017 Apr; 54(3):2167-2188. PubMed ID: 26927660
[TBL] [Abstract][Full Text] [Related]
13. CX3CL1/CX3CR1 axis attenuates early brain injury via promoting the delivery of exosomal microRNA-124 from neuron to microglia after subarachnoid hemorrhage.
Chen X; Jiang M; Li H; Wang Y; Shen H; Li X; Zhang Y; Wu J; Yu Z; Chen G
J Neuroinflammation; 2020 Jul; 17(1):209. PubMed ID: 32664984
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Tat disrupts CX3CL1-CX3CR1 axis in microglia via the NF-κBYY1 pathway.
Duan M; Yao H; Cai Y; Liao K; Seth P; Buch S
Curr HIV Res; 2014; 12(3):189-200. PubMed ID: 24862326
[TBL] [Abstract][Full Text] [Related]
15. Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies.
Ferretti E; Pistoia V; Corcione A
Mediators Inflamm; 2014; 2014():480941. PubMed ID: 24799766
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a protective role of the CX3CL1/CX3CR1 axis in a model of amyotrophic lateral sclerosis.
Liu C; Hong K; Chen H; Niu Y; Duan W; Liu Y; Ji Y; Deng B; Li Y; Li Z; Wen D; Li C
Biol Chem; 2019 Apr; 400(5):651-661. PubMed ID: 30352020
[TBL] [Abstract][Full Text] [Related]
17. Expression changes of CX3CL1 and CX3CR1 proteins in the hippocampal CA1 field of the gerbil following transient global cerebral ischemia.
Ahn JH; Kim DW; Park JH; Lee TK; Lee HA; Won MH; Lee CH
Int J Mol Med; 2019 Sep; 44(3):939-948. PubMed ID: 31524247
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the activation and recruitment of microglia-like cells protects against neomycin-induced ototoxicity.
Sun S; Yu H; Yu H; Honglin M; Ni W; Zhang Y; Guo L; He Y; Xue Z; Ni Y; Li J; Feng Y; Chen Y; Shao R; Chai R; Li H
Mol Neurobiol; 2015 Feb; 51(1):252-67. PubMed ID: 24781382
[TBL] [Abstract][Full Text] [Related]
19. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.
Hughes PM; Botham MS; Frentzel S; Mir A; Perry VH
Glia; 2002 Mar; 37(4):314-27. PubMed ID: 11870871
[TBL] [Abstract][Full Text] [Related]
20. The Cytokine CX3CL1 and ADAMs/MMPs in Concerted Cross-Talk Influencing Neurodegenerative Diseases.
Iemmolo M; Ghersi G; Bivona G
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
